Evidence map›Paper›PMID 40686656›Full record

ArticleGlobal epidemiology2025

Do certain blood groups increase COVID-19 severity and mortality?

Tegene Atamenta Kitaw, Ribka Nigatu Haile

Abstract read
In one paragraph

Article in Global epidemiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Tegene Atamenta KitawDepartment of Nursing, College of Health Science, Woldia University, Woldia, Ethiopia.
Ribka Nigatu HaileDepartment of Nursing, College of Health Science, Woldia University, Woldia, Ethiopia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The existence of a relationship between the ABO blood group and COVID-19 severity and mortality is still an unresolved concern. Some studies report that groups O and A show a lower and higher risk of developing severe COVID-19 and mortality, respectively. Some studies also report the reverse. There are inconclusive results from different studies. Thus, this study sought to determine the possible associations of ABO blood type with COVID-19 severity and mortality. Methods: A retrospective study was conducted among 570 adults with real-time reverse transcription-polymerase chain reaction confirmed positive COVID-19 patients attending Eka Kotebe General Hospital, COVID-19 Treatment Center. A Kaplan-Meier survival curve was computed to examine the difference in survival experience between ABO blood groups. Multinomial and binary logistic regression models were fitted to determine the association between ABO blood group with COVID-19 severity and mortality, respectively. Result: 238 (41.8 %) COVID-19 patients had blood group B, followed by 201 (35.3 %) A, 82 (14.4 %) O, and 49 (8.6 %) AB blood type. 23.68 % of participants develop severe COVID-19. Overall, 15.26 % COVID-19-related mortality was found. No difference in survival experience was observed between ABO blood types. There was no statistically significant association between ABO blood type and COVID-19 severity, and mortality. Conclusion: We found no relationship between ABO blood group differences and COVID-19 severity, and mortality. Further, well-design-controlled studies are suggested to explore the potential link of ABO blood group with COVID-19 severity and mortality.

Indexed as

ABO blood typesCOVID-19 severityMortality

Identifiers

PMID40686656
PMCPMC12274851

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.